MANE Overview

Veradermics, Incorporated is a late clinical-stage biopharmaceutical company. The Company is focused on developing innovative therapeutics to address pervasive treatment challenges in highly prevalent aesthetic and dermatological conditions. Its initial focus is developing better treatments for pattern hair loss (PHL). The Company is developing VDPHL01 as an oral, non-hormonal treatment for men and women with PHL to reduce the barriers to wide adoption of chronic hair loss therapy and potentially transform PHL treatment. VDPHL01 is an oral, ER formulation of minoxidil, a proven hair growth agent, designed to maximize minoxidil’s impact on hair restoration while minimizing the risk of cardiac activity. The Company is conducting a Phase II clinical trial evaluating VDPHL01 in male and female patients with mild-to-moderate PHL.

Wall Street analysts forecast MANE stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for MANE is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Veradermics Inc revenue for the last quarter amounts to -23.01M USD, increased 285.38

Veradermics Inc. EPS for the last quarter amounts to -23633000.00 USD, decreased

Veradermics Inc (MANE) has 21 emplpoyees as of May 11 2026.

Today MANE has the market capitalization of 4.37B USD.